{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:39:12Z","timestamp":1792694352912,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":265,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032714","name":"Conceivable Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n Does cost-to-baby, expressed as a percentage of median household income (HHI), predict population-level utilization of ART across countries?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n ART affordability follows a power-law relationship with population-level utilization (R2\u2009=\u20090.77\u20130.84), with highest-utilization countries consistently achieving gross cost-to-baby below 100% and net out-of-pocket cost-to-baby below 50% of median HHI.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Cost has been consistently identified as a dominant barrier to ART access worldwide, and earlier cross-national work has shown that per-cycle IVF cost as a proportion of disposable income is associated with national utilization. However, no prior analysis has used the cumulative cost of achieving a live birth, normalized it to median HHI, tested a non-linear functional form, or separated gross from net (out-of-pocket) cost as independent predictors.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n Cross-national study using secondary aggregate data from ART registries and economic\/demographic agencies for reporting years 2021\u20132023, covering 22 countries and regions that together represent more than 95% of estimated global ART cycle volume.<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n ART cycle volumes and live births were extracted from ICMART, ESHRE EIM, CDC NASS, CARTR, HFEA, REDLARA, ANZARD, and national registries. Median after-tax disposable HHI data were sourced from the Organisation for Economic Cooperation and Development (OECD) and World Bank, while female population aged 15\u201349\u2009years and total live births were obtained from the United Nations Population Division. Gross cost-to-baby was calculated as the product of mean per-cycle cost (including embryo transfer, preimplantation genetic testing weighted by national usage, and medications) and the age-weighted number of cycles required to achieve a live birth. Net out-of-pocket cost-to-baby was derived after applying published reimbursement schedules, subsidies, and tax benefits, with structured estimates where authoritative published data were unavailable. Both metrics were expressed as a percentage of median HHI. Utilization was measured as the percentage of total national live births achieved via ART and as ART births per 1000 women aged 15\u201349\u2009years. Power-law (log-log) regression was fitted by ordinary least squares; a subgroup analysis was performed for women aged 38\u201349\u2009years. A Monte Carlo probabilistic sensitivity analysis (10\u00a0000 iterations; Program Evaluation and Review Technique (PERT) distributions with uncertainty bands of \u00b15%, \u00b17.5%, or \u00b110% calibrated to data-source quality) generated 90% simulation envelopes around each baseline regression.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n Gross cost-to-baby varied more than 12-fold across countries, ranging from 66% of median HHI in Israel to 833% in Africa (excluding Egypt, Tunisia, and South Africa); net out-of-pocket cost-to-baby ranged from 13% to 825% of median HHI. Power-law regression demonstrated strong inverse relationships between affordability and utilization across all four model specifications (gross cost vs ART births per 1000 women aged 15\u201349\u2009years: R2 = 0.84; net cost vs the same measure: R2 = 0.84; gross cost vs percentage of births via ART: R2 = 0.83; net cost vs percentage of births via ART: R2 = 0.77). The model-implied elasticity indicated that halving net out-of-pocket cost-to-baby is associated with a 2.67-fold increase in ART births per 1000 women of reproductive age and halving gross cost-to-baby with a 5.12-fold increase. Countries with gross cost-to-baby below 100% and net cost-to-baby below 50% of median HHI consistently achieved the highest utilization (e.g. Israel 8.7% of births via ART; South Korea 11.8%; Spain 11.7%; Japan 9.3%). The power-law relationship was preserved in women aged 38\u201349\u2009years (R2\u2009=\u20090.76\u20130.85). Monte Carlo simulation envelopes were narrow across all four models, indicating that the affordability\u2013utilization gradient is robust to plausible variation in country-level input estimates.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n This is a cross-national, population-level (ecological) analysis. Since it uses aggregated, country-level data, the observed associations cannot support individual-level causal inference, may be subject to ecological confounding, and reverse causation through volume-driven economies of scale cannot be excluded. Registry data are heterogeneous across countries in reporting standards, cycle definitions, and completeness. Unmeasured confounders include cultural and religious attitudes, regulatory restrictions, clinic capacity constraints, and cross-border reproductive care. Net out-of-pocket cost estimates for a subset of countries were derived through structured triangulation that included AI-assisted synthesis and should be interpreted accordingly; the Monte Carlo analysis quantifies uncertainty in the affordability metrics but holds utilization outcomes fixed. The macro-level framework cannot address within-country inequities in ART access.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n Cost-to-baby relative to median HHI offers a standardized, policy-relevant affordability metric that builds on previous per-cycle approaches. The power-law relationship implies that affordability improvements yield the greatest marginal returns in countries where costs are highest relative to income. The independent predictive value of gross and net cost-to-baby identifies two complementary policy levers: provider-side efficiency (workforce expansion, technology adoption, and care-delivery efficiencies to bring gross cost-to-baby below 100% of median HHI) and demand-side coverage (insurance mandates, subsidies, or tax incentives to bring net out-of-pocket cost below 50%). Published generational accounting analyses indicate that the lifetime fiscal return on public ART investment exceeds its cost by 2.7- to 16-fold across 11 of 12 countries studied, supporting the underlying economic case.<\/jats:p>\n <\/jats:sec>\n \n FUNDING<\/jats:title>\n No specific funding was received; the study was supported by Conceivable Life Sciences.<\/jats:p>\n <\/jats:sec>\n \n DISCLOSURES<\/jats:title>\n G.S. is an employee and stock option holder at Conceivable Life Sciences. S.R. is an employee of Ontario Teachers\u2019 Pension Plan, has received consultancy fees from Conceivable Life Sciences and Zi\u00f6ra, and is a Director of Simbryo Technologies. A.C.-B. is an employee, shareholder, and company officer at Conceivable Life Sciences, and a shareholder in IVF 2.0. and Hope IVF Mexico. S.P. has received consultancy fees from Conceivable Life Sciences. S.K. is an employee, stock option holder, and company officer at Conceivable Life Sciences, has received consultancy fees from the WHO and Vitra Labs, and is Board Trustee of The King\u2019s Fund. A.M. is a shareholder and company officer at Conceivable Life Sciences and holds shares in TMRW Life Sciences. D.S. is a shareholder and board member at Oova, a board member of AutoIVF, an advisory board member of Evvy, Conceivable Life Sciences, and The US Fertility venture fund, and a general partner at the Special Situations Life Sciences Fund and Life Sciences Innovation Fund I\u2013II. G.D.A. is CEO of Advanced Reproductive Care Inc. (ARC Fertility), Chair of ICMART, and President of the World Endometriosis Research Foundation, and received consultancy fees from Pendant Health. Furthermore, G.S., A.C.-B., and A.M. declare inventorship on the US patents 12\u00a0178\u00a0475 B1 (automated sperm preparation) and 12\u00a0226\u00a0125 B2 (automated vitrification). A.C.-B. and A.M. declare inventorship on the US patents 12\u00a0349\u00a0940 B2 (automated oocyte denudation), 12\u00a0245\u00a0793 B2 (robotic handling systems for IVF laboratories), 12\u00a0180\u00a0441 B1 (laboratory workflow automation), 12\u00a0268\u00a0418 B2 (automated oocyte preparation), 12\u00a0310\u00a0625 B2 (automated ICSI), and 12\u00a0253\u00a0516 B2 (optical systems for IVF automation), as well as pending patent applications relating to automated dish preparation technology and automated vitrification systems.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION NUMBER<\/jats:title>\n N\/A.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/hropen\/hoag084","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:41:52Z","timestamp":1790077312000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-to-baby as a percentage of median household income predicts population-level access to ART: a global health economics analysis"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-2470","authenticated-orcid":false,"given":"Giuseppe","family":"Silvestri","sequence":"first","affiliation":[{"name":"Conceivable Life Sciences , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Rooks","sequence":"additional","affiliation":[{"name":"Ontario Teachers Pension Plan , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-3174","authenticated-orcid":false,"given":"Alejandro","family":"Chavez-Badiola","sequence":"additional","affiliation":[{"name":"Conceivable Life Sciences , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Perez","sequence":"additional","affiliation":[{"name":"Conceivable Life Sciences , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-4948","authenticated-orcid":false,"given":"Stephanie","family":"Kuku","sequence":"additional","affiliation":[{"name":"Conceivable Life Sciences , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Murray","sequence":"additional","affiliation":[{"name":"Conceivable Life Sciences , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1780-7003","authenticated-orcid":false,"given":"David","family":"Sable","sequence":"additional","affiliation":[{"name":"Special Situations Life Sciences and Life Sciences Innovation Fund , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-7629","authenticated-orcid":false,"given":"G David","family":"Adamson","sequence":"additional","affiliation":[{"name":"Equal3 APC , Denver, CO,","place":["USA"]},{"name":"Department of Obstetrics & Gynecology, Stanford University School of Medicine , Stanford, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026102213575159500_hoag084-B1","doi-asserted-by":"crossref","first-page":"1738726","DOI":"10.3389\/frph.2026.1738726","article-title":"Improving access to fertility treatment in Asia Pacific: consensus from an expert forum","volume":"8","author":"Abat","year":"2026","journal-title":"Front Reprod Health"},{"key":"2026102213575159500_hoag084-B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/WHE.09.28","article-title":"Global cultural and socioeconomic factors that influence access to assisted reproductive technologies","volume":"5","author":"Adamson","year":"2009","journal-title":"Womens Health (Lond)"},{"key":"2026102213575159500_hoag084-B3","doi-asserted-by":"crossref","first-page":"105697","DOI":"10.1016\/j.rbmo.2026.105697","article-title":"Declining global fertility and our future dependence on ART","volume":"53","author":"Aitken","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B5","doi-asserted-by":"crossref","first-page":"2050312120931988","DOI":"10.1177\/2050312120931988","article-title":"Cost-effectiveness of assisted reproductive technologies in Saudi Arabia: comparing in vitro fertilization with intrauterine insemination","volume":"8","author":"Almaslami","year":"2020","journal-title":"SAGE Open Med"},{"key":"2026102213575159500_hoag084-B7","doi-asserted-by":"crossref","first-page":"104353","DOI":"10.1016\/j.rbmo.2024.104353","article-title":"Assisted reproductive technologies in Africa: the African network and registry for ART, 2020","volume":"49","author":"Archary","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/humrep\/deaf049","article-title":"International Committee for Monitoring Assisted Reproductive Technologies (ICMART): world report for cycles conducted in 2017\u20132018","volume":"40","author":"Baker","year":"2025","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B9","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(24)00550-6","article-title":"Global fertility in 204 countries and territories, 1950\u20132021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Bhattacharjee","year":"2024","journal-title":"Lancet"},{"key":"2026102213575159500_hoag084-B10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/humrep\/dem046","article-title":"International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care","volume":"22","author":"Boivin","year":"2007","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B11","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006","edition":"1st edn"},{"key":"2026102213575159500_hoag084-B12","author":"CARTR-Plus & BORN Ontario","year":"2025"},{"key":"2026102213575159500_hoag084-B13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10729-014-9282-2","article-title":"IVF cycle cost estimation using activity based costing and Monte Carlo simulation","volume":"19","author":"Cassettari","year":"2016","journal-title":"Health Care Manag Sci"},{"key":"2026102213575159500_hoag084-B14","author":"CDC"},{"key":"2026102213575159500_hoag084-B15","doi-asserted-by":"crossref","first-page":"105542","DOI":"10.1016\/j.rbmo.2026.105542","article-title":"Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international perspective","volume":"52","author":"Chaillot","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B16","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/humrep\/deab198","article-title":"International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2014","volume":"36","author":"Chambers","year":"2021","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.fertnstert.2013.09.005","article-title":"The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis","volume":"101","author":"Chambers","year":"2014","journal-title":"Fertil Steril"},{"key":"2026102213575159500_hoag084-B18","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.fertnstert.2009.04.029","article-title":"The economic impact of assisted reproductive technology: a review of selected developed countries","volume":"91","author":"Chambers","year":"2009","journal-title":"Fertil Steril"},{"key":"2026102213575159500_hoag084-B19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/humrep\/deae271","article-title":"Estimating the public economic gains in Taiwan from in vitro fertilization (IVF) subsidy changes implemented in 2021","volume":"40","author":"Chen","year":"2025","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/humupd\/dmaa047","article-title":"IVF and other ART in low- and middle-income countries: a systematic landscape analysis","volume":"27","author":"Chiware","year":"2021","journal-title":"Hum Reprod Update"},{"key":"2026102213575159500_hoag084-B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"Claxton","year":"2005","journal-title":"Health Econ"},{"key":"2026102213575159500_hoag084-B22","doi-asserted-by":"crossref","first-page":"105738","DOI":"10.1016\/j.rbmo.2026.105738","article-title":"The economics of hope: valuing the long-term fiscal returns from assisted reproduction","volume":"53","author":"Connolly","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/humrep\/den435","article-title":"Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK","volume":"24","author":"Connolly","year":"2009","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B24","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1093\/humrep\/dep260","article-title":"The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment","volume":"24","author":"Connolly","year":"2009","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/humupd\/dmq013","article-title":"The costs and consequences of assisted reproductive technology: an economic perspective","volume":"16","author":"Connolly","year":"2010","journal-title":"Hum Reprod Update"},{"key":"2026102213575159500_hoag084-B26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.fertnstert.2022.12.011","article-title":"The intergenerational economics of infertility, childrearing, and assisted reproduction","volume":"119","author":"Connolly","year":"2023","journal-title":"Fertil Steril"},{"key":"2026102213575159500_hoag084-B27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.36469\/jheor.2025.133796","article-title":"Estimating the fiscal value of children conceived from assisted reproduction technology in Australia applying a public economic perspective","volume":"12","author":"Connolly","year":"2025","journal-title":"J Health Econ Outcomes Res"},{"key":"2026102213575159500_hoag084-B28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rbms.2020.08.001","article-title":"Estimating the government public economic benefits attributed to investing in assisted reproductive technology: a South African case study","volume":"12","author":"Connolly","year":"2021","journal-title":"Reprod Biomed Soc Online"},{"key":"2026102213575159500_hoag084-B29","first-page":"598","article-title":"Long-term economic benefits attributed to IVF-conceived children: a lifetime tax calculation","volume":"14","author":"Connolly","year":"2008","journal-title":"Am J Manag Care"},{"key":"2026102213575159500_hoag084-B30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.rbmo.2011.09.011","article-title":"The long-term fiscal impact of funding cuts to Danish public fertility clinics","volume":"23","author":"Connolly","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rbmo.2020.03.007","article-title":"ART utilization: an indicator of access to infertility care","volume":"41","author":"Dyer","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B32","doi-asserted-by":"crossref","first-page":"105230","DOI":"10.1016\/j.rbmo.2025.105230","article-title":"Assisted reproductive technologies in Africa: the African Network and Registry for ART, 2021 and 2022","volume":"52","author":"Dyer","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B33","author":"Ernst & Young LLP","year":"2015"},{"key":"2026102213575159500_hoag084-B34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/humupd\/dmad028","article-title":"Declining global fertility rates and the implications for family planning and family building: an IFFS consensus document based on a narrative review of the literature","volume":"30","author":"Fauser","year":"2024","journal-title":"Hum Reprod Update"},{"key":"2026102213575159500_hoag084-B35","author":"HFEA","year":"2025"},{"key":"2026102213575159500_hoag084-B37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fendo.2020.00458","article-title":"Assisted reproductive technology in China: results generated from data reporting system by CSRM from 2013 to 2016","volume":"11","author":"Hu","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026102213575159500_hoag084-B38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/humupd\/dmv016","article-title":"Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century","volume":"21","author":"Inhorn","year":"2015","journal-title":"Hum Reprod Update"},{"key":"2026102213575159500_hoag084-B4","first-page":"1","article-title":"International federation of fertility societies\u2019 surveillance (IFFS) 2019: global trends in reproductive policy and practice, 8th edition","volume":"4","year":"2019","journal-title":"Glob Reprod Health"},{"key":"2026102213575159500_hoag084-B36","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/GRH.0000000000000058","article-title":"International Federation of Fertility Societies\u2019 Surveillance (IFFS) 2022: global trends in reproductive policy and practice, 9th edition","volume":"7","year":"2022","journal-title":"Glob Reprod Health"},{"key":"2026102213575159500_hoag084-B39","author":"Israel Ministry of Health","year":"2024"},{"key":"2026102213575159500_hoag084-B40","doi-asserted-by":"crossref","first-page":"e12620","DOI":"10.1002\/rmb2.12620","article-title":"Assisted reproductive technology in Japan: a summary report for 2022 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology","volume":"23","author":"Katagiri","year":"2024","journal-title":"Reprod Med Biol"},{"key":"2026102213575159500_hoag084-B41","doi-asserted-by":"crossref","first-page":"1053719","DOI":"10.3389\/fmedt.2022.1053719","article-title":"Valuing infertility treatment: why QALYs are inadequate, and an alternative approach to cost-effectiveness thresholds","volume":"4","author":"Keller","year":"2022","journal-title":"Front Med Technol"},{"key":"2026102213575159500_hoag084-B6"},{"key":"2026102213575159500_hoag084-B42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5653\/cerm.2025.08872","article-title":"Assisted reproductive technology trends in Korea: annual report for 2022","volume":"52","author":"Lee","year":"2025","journal-title":"Clin Exp Reprod Med"},{"key":"2026102213575159500_hoag084-B43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.rbms.2016.04.001","article-title":"Long-term fiscal implications of funding assisted reproduction: a generational accounting model for Spain","volume":"1","author":"Matorras","year":"2015","journal-title":"Reprod Biomed Soc Online"},{"key":"2026102213575159500_hoag084-B44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.rbmo.2013.10.002","article-title":"Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands","volume":"28","author":"Moolenaar","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B45","doi-asserted-by":"crossref","first-page":"hoad007","DOI":"10.1093\/hropen\/hoad007","article-title":"Financial costs of assisted reproductive technology for patients in low-and middle-income countries: a systematic review","volume":"2023","author":"Njagi","year":"2023","journal-title":"Hum Reprod Open"},{"key":"2026102213575159500_hoag084-B46","author":"OECD","year":"2026"},{"key":"2026102213575159500_hoag084-B47","first-page":"326","article-title":"Global in vitro fertilization utilization: how does the United States compare?","volume":"4","author":"Peipert","year":"2023","journal-title":"F S Rep"},{"key":"2026102213575159500_hoag084-B48","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.rbmo.2026.105780","article-title":"A plan for universal access to fertility care","volume":"53","author":"Sable","year":"2026","journal-title":"Reprod Biomed Online"},{"key":"2026102213575159500_hoag084-B49","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/humrep\/deaf179","article-title":"ART in Europe, 2020: results generated from European registries by ESHRE\u2020","volume":"40","author":"Smeenk","year":"2025","journal-title":"Hum Reprod"},{"key":"2026102213575159500_hoag084-B50","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1001\/jama.2015.17296","article-title":"Live-birth rate associated with repeat in vitro fertilization treatment cycles","volume":"314","author":"Smith","year":"2015","journal-title":"JAMA"},{"key":"2026102213575159500_hoag084-B51","author":"Sociedad Espa\u00f1ola de Fertilidad","year":"2024"},{"key":"2026102213575159500_hoag084-B52","author":"Suzhou Basecare Corporation Ltd","year":"2025"},{"key":"2026102213575159500_hoag084-B53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/1403494808095086","article-title":"Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective","volume":"36","author":"Svensson","year":"2008","journal-title":"Scand J Public Health"},{"key":"2026102213575159500_hoag084-B54","author":"Taiwan Ministry of Health and Welfare","year":"2024"},{"key":"2026102213575159500_hoag084-B55","author":"United Nations, Department of Economic and Social Affairs, Population Division","year":"2024"},{"key":"2026102213575159500_hoag084-B56","volume-title":"Risk Analysis: A Quantitative Guide","author":"Vose","year":"2008","edition":"3rd edn"},{"key":"2026102213575159500_hoag084-B57","author":"WHO Infertility Prevalence Estimates 1990\u20132021","year":"2023"},{"key":"2026102213575159500_hoag084-B58","author":"World Bank","year":"2021"},{"key":"2026102213575159500_hoag084-B59","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.rbmo.2024.104413","article-title":"Assisted reproductive technologies in Latin America: the Latin American Registry, 2021","volume":"50","author":"Zegers-Hochschild","year":"2025","journal-title":"Reprod Biomed Online"}],"container-title":["Human Reproduction Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hropen\/advance-article-pdf\/doi\/10.1093\/hropen\/hoag084\/71326786\/hoag084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2026\/4\/hoag084\/71326786\/hoag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hropen\/article-pdf\/2026\/4\/hoag084\/71326786\/hoag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:58:04Z","timestamp":1792691884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hropen\/article\/doi\/10.1093\/hropen\/hoag084\/8830113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1093\/hropen\/hoag084","relation":{},"ISSN":["2399-3529"],"issn-type":[{"value":"2399-3529","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"hoag084"}}